Business Description
Bristol-Myers Squibb Co
NAICS : 325412
SIC : 2834
ISIN : US1101221083
Share Class Description:
MEX:BMY: Ordinary SharesCompare
Compare
Traded in other countries / regions
BMY.USA0R1F.UKBMY.MexicoBRM.GermanyBMY.ArgentinaBMY.PeruBMYB34.Brazil1BMY.ItalyBMYS.AustriaBMY.Switzerland IPO Date
2004-11-11Description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.3 | |||||
| Equity-to-Asset | 0.31 | |||||
| Debt-to-Equity | 1.41 | |||||
| Debt-to-EBITDA | 2.14 | |||||
| Interest Coverage | 7.03 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 2.24 | |||||
| Beneish M-Score | -2.79 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 4.8 | |||||
| 3-Year EBITDA Growth Rate | 62.2 | |||||
| 3-Year EPS without NRI Growth Rate | 5.3 | |||||
| 3-Year FCF Growth Rate | 1.1 | |||||
| 3-Year Book Growth Rate | -5.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -4.18 | |||||
| Future 3-5Y Total Revenue Growth Rate | -1 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 29.79 | |||||
| 9-Day RSI | 28.69 | |||||
| 14-Day RSI | 32.98 | |||||
| 6-1 Month Momentum % | -15.92 | |||||
| 12-1 Month Momentum % | -30.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.43 | |||||
| Quick Ratio | 1.31 | |||||
| Cash Ratio | 0.55 | |||||
| Days Inventory | 84.69 | |||||
| Days Sales Outstanding | 67.18 | |||||
| Days Payable | 104.96 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 4.93 | |||||
| Dividend Payout Ratio | 0.31 | |||||
| 3-Year Dividend Growth Rate | 7.9 | |||||
| Forward Dividend Yield % | 4.88 | |||||
| 5-Year Yield-on-Cost % | 7.24 | |||||
| 3-Year Average Share Buyback Ratio | 3.1 | |||||
| Shareholder Yield % | 12.79 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 76.24 | |||||
| Operating Margin % | 18.21 | |||||
| Net Margin % | 17.83 | |||||
| FCF Margin % | 28.04 | |||||
| ROE % | 26.18 | |||||
| ROA % | 8.52 | |||||
| ROIC % | 9.6 | |||||
| ROC (Joel Greenblatt) % | 124.45 | |||||
| ROCE % | 13.19 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 12.51 | |||||
| Forward PE Ratio | 6.89 | |||||
| PE Ratio without NRI | 6.44 | |||||
| Shiller PE Ratio | 25.4 | |||||
| Price-to-Owner-Earnings | 8.38 | |||||
| PEG Ratio | 0.26 | |||||
| PS Ratio | 2.23 | |||||
| PB Ratio | 3.32 | |||||
| Price-to-Free-Cash-Flow | 7.9 | |||||
| Price-to-Operating-Cash-Flow | 7.21 | |||||
| EV-to-EBIT | 13.23 | |||||
| EV-to-Forward-EBIT | 9.44 | |||||
| EV-to-EBITDA | 6.56 | |||||
| EV-to-Forward-EBITDA | 7.06 | |||||
| EV-to-Revenue | 2.82 | |||||
| EV-to-Forward-Revenue | 2.77 | |||||
| EV-to-FCF | 10.04 | |||||
| Price-to-Projected-FCF | 0.67 | |||||
| Price-to-DCF (Earnings Based) | 0.22 | |||||
| Price-to-DCF (FCF Based) | 0.24 | |||||
| Price-to-Median-PS-Value | 0.56 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.29 | |||||
| Earnings Yield (Greenblatt) % | 7.56 | |||||
| FCF Yield % | 12.92 | |||||
| Forward Rate of Return (Yacktman) % | 32.09 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bristol-Myers Squibb Co Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 789,128.349 | ||
| EPS (TTM) (MXN) | 67.797 | ||
| Beta | -0.09 | ||
| Volatility % | 13.49 | ||
| 14-Day RSI | 32.98 | ||
| 14-Day ATR (MXN) | 8.651657 | ||
| 20-Day SMA (MXN) | 846.4855 | ||
| 12-1 Month Momentum % | -30.98 | ||
| 52-Week Range (MXN) | 805.01 - 1275.99 | ||
| Shares Outstanding (Mil) | 2,026.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bristol-Myers Squibb Co Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bristol-Myers Squibb Co Stock Events
| Event | Date | Price(MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
Bristol-Myers Squibb Co Frequently Asked Questions
What is Bristol-Myers Squibb Co(MEX:BMY)'s stock price today?
The current price of MEX:BMY is MXN815.00. The 52 week high of MEX:BMY is MXN1275.99 and 52 week low is MXN805.01.
When is next earnings date of Bristol-Myers Squibb Co(MEX:BMY)?
The next earnings date of Bristol-Myers Squibb Co(MEX:BMY) is 2024-04-25.
Does Bristol-Myers Squibb Co(MEX:BMY) pay dividends? If so, how much?
The Dividend Yield %  of Bristol-Myers Squibb Co(MEX:BMY) is 4.93% (As of Today), Highest Dividend Payout Ratio of Bristol-Myers Squibb Co(MEX:BMY) was 0.78. The lowest was 0.27. And the median was 0.38. The  Forward Dividend Yield % of Bristol-Myers Squibb Co(MEX:BMY) is 4.88%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers